Stern, L;
Schmidt, C;
Kocheise, L;
Joerg, V;
Casar, C;
Walter, A;
Drenth, JPH;
... Schulze, K; + view all
(2024)
Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma.
Annals of Hepatology
, 29
(6)
, Article 101534. 10.1016/j.aohep.2024.101534.
Preview |
Text
1-s2.0-S1665268124003284-main.pdf - Published Version Download (1MB) | Preview |
Abstract
Introduction and Objectives: Autoimmune liver diseases (AILD) are rare causes hepatocellular carcinoma (HCC), and data on the efficacy and tolerability of anti-tumor therapies are scarce. This pan-European study aimed to assess outcomes in AILD-HCC patients treated with tyrosine kinase inhibitors (TKIs) or transarterial chemoembolization (TACE) compared with patients with more common HCC etiologies, including viral, alcoholic or non-alcoholic fatty liver disease. / Materials and Methods: 107 patients with HCC-AILD (AIH:55; PBC:52) treated at 13 European centres between 1996 and 2020 were included. 65 received TACE and 28 received TKI therapy. 43 (66 %) were female (median age 73 years) with HCC tumor stage BCLC A (34 %), B (46 %), C (9 %) or D (11 %). For each treatment type, propensity score matching was used to match AILD to non-AILD-HCC on a 1:1 basis, yielding in a final cohort of 130 TACE and 56 TKI patients for comparative analyses of median overall survival (mOS) and treatment tolerability. / Results: HCC-AILD patients showed comparable mOS to controls for both TACE (19.5 vs. 22.1 months, p = 0.9) and TKI (15.4 vs. 15.1 months, p = 0.5). Adverse events were less frequent in AILD-HCC patients than controls (33 % % vs. 62 %, p = 0.003). For TKIs, there were no significant differences in adverse events (73% vs. 86%, p = 0.2) or interruption rates (44% vs. 36 %, p = 0.7). / Conclusions: In summary, this study demonstrates comparable mOS for AILD-HCC patients undergoing local and systemic treatments, with better tolerability than HCC of other causes. TKIs remain important therapeutic options for AILD-HCC patients, particularly given their exclusion from recent immunotherapy trials.
| Type: | Article |
|---|---|
| Title: | Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma |
| Location: | Mexico |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.aohep.2024.101534 |
| Publisher version: | https://doi.org/10.1016/j.aohep.2024.101534 |
| Language: | English |
| Additional information: | Copyright © 2024 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inst for Liver and Digestive Hlth |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10197917 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
